These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 9483371

  • 1. Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients.
    Lunetta M, Di Mauro M, Le Moli R, Nicoletti F.
    Diabetes Res Clin Pract; 1997 Nov; 38(2):81-9. PubMed ID: 9483371
    [Abstract] [Full Text] [Related]

  • 2. Effect of octreotide on insulin requirement, hepatic glucose production, growth hormone, glucagon and c-peptide levels in type 2 diabetic patients with chronic renal failure or normal renal function.
    Di Mauro M, Papalia G, Le Moli R, Nativo B, Nicoletti F, Lunetta M.
    Diabetes Res Clin Pract; 2001 Jan; 51(1):45-50. PubMed ID: 11137181
    [Abstract] [Full Text] [Related]

  • 3. Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients.
    Bruttomesso D, Fongher C, Silvestri B, Barberio S, Marescotti MC, Iori E, Valerio A, Crazzolara D, Pianta A, Tiengo A, Del Prato S.
    Diabetes Res Clin Pract; 2001 Feb; 51(2):97-105. PubMed ID: 11165689
    [Abstract] [Full Text] [Related]

  • 4. Effects of the somatostatin analog, octreotide, on glucose metabolism and insulin sensitivity in insulin-dependent diabetes mellitus.
    Orskov L, Møller N, Bak JF, Pørksen N, Schmitz O.
    Metabolism; 1996 Feb; 45(2):211-7. PubMed ID: 8596492
    [Abstract] [Full Text] [Related]

  • 5. Effect of octreotide on blood glucose and counterregulatory hormones in insulin-dependent diabetic patients: the role of dose and route of administration.
    Lunetta M, De Mauro M, Le Moli R, Nicoletti F.
    Eur J Clin Pharmacol; 1996 Feb; 51(2):139-44. PubMed ID: 8911878
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of octreotide on growth hormone, IGF-I, IGFBP-3, glucagon, cortisol and epinephrine response to insulin-induced hypoglycaemia in insulin-dependent diabetic patients.
    Lunetta M, Di Mauro M, Le Moli R, Nicoletti F.
    Diabetes Metab; 1997 Dec; 23(6):524-7. PubMed ID: 9496559
    [Abstract] [Full Text] [Related]

  • 8. Assessment of hepatic insulin action in obese type 2 diabetic patients.
    Staehr P, Hother-Nielsen O, Levin K, Holst JJ, Beck-Nielsen H.
    Diabetes; 2001 Jun; 50(6):1363-70. PubMed ID: 11375337
    [Abstract] [Full Text] [Related]

  • 9. Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects.
    Plöckinger U, Holst JJ, Messerschmidt D, Hopfenmüller W, Quabbe HJ.
    Eur J Endocrinol; 1999 Jun; 140(6):538-44. PubMed ID: 10377503
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxide.
    Björk E, Berne C, Karlsson FA.
    Diabetes Care; 1998 Mar; 21(3):427-30. PubMed ID: 9540027
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
    Riccio A, Avogaro A, Valerio A, Zappella A, Tiengo A, Del Prato S.
    Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
    [Abstract] [Full Text] [Related]

  • 17. Differential effects of ambient blood glucose level and degree of obesity on basal serum C-peptide level and the C-peptide response to glucose and glucagon in non-insulin-dependent diabetes mellitus.
    Park SW, Ihm SH, Yoo HJ, Park JY, Lee KU.
    Diabetes Res Clin Pract; 1997 Sep; 37(3):165-71. PubMed ID: 9306037
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
    Kanc K, Janssen MM, Keulen ET, Jacobs MA, Popp-Snijders C, Snoek FJ, Heine RJ.
    Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
    [Abstract] [Full Text] [Related]

  • 20. Effects of long-acting somatostatin analogue (Sandostatin) on manifest diabetic ketoacidosis.
    Yun YS, Lee HC, Park CS, Chang KH, Cho CH, Song YD, Lim SK, Kim KR, Huh KB.
    J Diabetes Complications; 1999 Mar; 13(5-6):288-92. PubMed ID: 10765004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.